A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Reason given: Study terminated for strategic business reasons
Key facts
- Where
- Bay City, Bellevue, Blackfoot, Boca Raton, Chapel Hill, Columbia, Columbus, Dallas, Honolulu, Houston, Idaho Falls, Jacksonville, Kingwood, Lake Forest, Lawrenceville, Long Beach, Miami, Miami Lakes, Newburgh, Northridge, Orlando, The Villages, Tulsa, Walnut Creek, and Yuma, United StatesSee the 25 sites
- Phase
- Phase 2
Where in United States
- Great Lakes Research Group, Inc.Bay City, United StatesNo longer taking part
- Northwest Clinical Research CenterBellevue, United StatesNo longer taking part
- Bingham Memorial HospitalBlackfoot, United StatesNo longer taking part
- Excel Medical Clinical TrialsBoca Raton, United StatesNo longer taking part
- University of North Carolina Medical CenterChapel Hill, United StatesNo longer taking part
- Kur Research - Columbia MedicalColumbia, United StatesNo longer taking part
- Remington Davis, Inc.Columbus, United StatesNo longer taking part
- Velocity Clinical Research, DallasDallas, United StatesNo longer taking part
- East-West Medical Research InstituteHonolulu, United StatesNo longer taking part
- PlanIt Research, PLLCHouston, United StatesNo longer taking part
- Family First Medical CenterIdaho Falls, United StatesNo longer taking part
- Clinical Neuroscience Solutions, Inc. dba CNS HealthcareJacksonville, United StatesNo longer taking part
- Activian Clinical ResearchKingwood, United StatesNo longer taking part
- Orange County Research CenterLake Forest, United StatesNo longer taking part
- Balanced Life Health Care Solutions/SKYCRNGLawrenceville, United StatesNo longer taking part
- Healthy Brain ClinicLong Beach, United StatesNo longer taking part
- L&C Professional Medical Research InstituteMiami, United StatesNo longer taking part
- Global Health Research Center, Inc.Miami Lakes, United StatesNo longer taking part
- Deaconess Clinic- GatewayNewburgh, United StatesNo longer taking part
- Valley Clinical Trials, Inc.Northridge, United StatesNo longer taking part
- Charter Research - Winter ParkOrlando, United StatesNo longer taking part
- Charter Research - Lady LakeThe Villages, United StatesNo longer taking part
- Central States ResearchTulsa, United StatesNo longer taking part
- Diablo Clinical Research, Inc.Walnut Creek, United StatesNo longer taking part
- Yuma Clinical TrialsYuma, United StatesNo longer taking part
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06901349
- Record updated
- 24 September 2025
- Original description
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.Read full original descriptionShow less
A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
Inclusion: Have type 2 diabetes; Have a BMI of ≥27 kilograms per square meter (kg/m2); Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss).
Exclusion: Have a prior or planned surgical treatment for obesity,; Have any of the following cardiovascular conditions within 3 months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening; Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma; Have poorly controlled hypertension; Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure; Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes; Have ongoing or a history of bradyarrhythmias other than sinus bradycardia; Have renal impairment; Have a history of symptomatic gallbladder disease within the past 2 years; Have signs and symptoms of any liver disease; Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality; Have a history of acute or chronic pancreatitis.